850-P: Greater HbA1c Reduction with iGlarLixi vs. Insulin Glargine and Lixisenatide Regardless of Levels at Screening: Subgroup Analysis of the LixiLan-O Asia Pacific Trial

• Published in: Diabetes (New York, N.Y.) Vol. 71; no. Supplement_1
• Main Authors: HE, YIFAN, YANG, WENYING, XIAOLIN, DONG, YUAN, GUOYUE, LIU, MING, XIAO, JIANZHONG, GU, SHENGHONG, CHEN, LIJUAN, SOUHAMI, ELISABETH
• Format: Journal Article
• Language: English
• Published: New York American Diabetes Association 01.06.2022
• Subjects: Diabetes; Diabetes mellitus (non-insulin dependent); Glucose; Hemoglobin; Hypoglycemia; Insulin; Metformin

Introduction: LixiLan-O-AP (NCT03798054) showed greater HbA1c improvement with iGlarLixi vs. iGlar or Lixi in Asian Pacific adults with type 2 diabetes (T2D) . This pre-defined analysis assessed iGlarLixi efficacy by HbA1c levels at screening. Methods: Adults (N=878) with suboptimally controlled T2D...